The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended that Inluriyo ( imlunestrant, Eli Lilly Nederland B.V.) be given marketing authorization for the treatment of adults with locally advanced or metastatic breast cancer with an activating estrogen receptor 1 (ESR1) mutation…
Read More
About The Author
